<p>Tenaya Therapeutics（纳斯达克代码：TNYA - 获取免费报告）在周五向投资者发布的报告中，投资分析师 HC Wainwright 将其目标价格从 5.00 美元下调至 3.00 美元，Benzinga 报道。该公司目前对该股票的评级为 “买入”。HC Wainwright 的目标价格意味着该股票当前价格的潜在上涨幅度为 260.14%。</p>
<p>TNYA 已经成为其他几份研究报告的主题。Weiss Ratings 在 10 月 8 日的报告中重申了对 Tenaya Therapeutics 股票的 “卖出（d-）” 评级。Chardan Capital 在周五的研究报告中将 Tenaya Therapeutics 的目标价格从 9.00 美元下调至 8.00 美元，并对该股票给予 “买入” 评级。四位分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，共识目标价格为 5.50 美元。</p>
<p>获取 <strong>Tenaya Therapeutics</strong> 的提醒：</p>
<p><strong>查看我们对 Tenaya Therapeutics 的最新股票分析</strong></p>
<h2>Tenaya Therapeutics 价格表现</h2>
<p>周五，TNYA 下跌 0.53 美元，达到 0.83 美元。该股票交易了 42,596,872 股，较其平均交易量 3,261,775 股有所增加。该公司的 50 日移动平均价格为 1.51 美元，200 日移动平均价格为 1.11 美元。该公司的市值为 1.387 亿美金，市盈率为-1.06，贝塔值为 3.13。Tenaya Therapeutics 的 52 周低点为 0.36 美元，52 周高点为 2.95 美元。</p>
<p>Tenaya Therapeutics（纳斯达克代码：TNYA - 获取免费报告）最后一次公布季度财报是在 11 月 10 日，报告显示该公司每股收益为-0.12 美元，超出分析师共识预期的-0.15 美元，超出幅度为 0.03 美元。整体来看，股票分析师预测 Tenaya Therapeutics 在当前财政年度的每股收益为-1.35 美元。</p>
<h2>对 Tenaya Therapeutics 的对冲基金看法</h2>
<p>几家大型投资者最近对该公司的持仓进行了调整。Woodline Partners LP 在第一季度将其在 Tenaya Therapeutics 的持仓提高了 30,563.2%。Woodline Partners LP 目前拥有 5,916,167 股该公司的股票，价值 3,373,000 美元，在此期间又增持了 5,896,873 股。Millennium Management LLC 在第三季度将其在 Tenaya Therapeutics 的持仓增加了 561.7%。Millennium Management LLC 目前拥有 4,504,592 股该公司的股票，价值 7,297,000 美元，在上个季度又购买了 3,823,848 股。AQR Capital Management LLC 在第一季度获得了 Tenaya Therapeutics 的新头寸，价值约 442,000 美元。Schonfeld Strategic Advisors LLC 在第三季度购买了 Tenaya Therapeutics 的新头寸，价值约 755,000 美元。最后，GSA Capital Partners LLP 在第三季度购买了 Tenaya Therapeutics 的新头寸，价值 748,000 美元。目前 90.54% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于 Tenaya Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Tenaya Therapeutics, Inc 是一家生物技术公司，专注于在美国发现、开发和提供心脏病治疗方案。它通过基因编辑、细胞再生和基因添加来开发其产品。该公司正在开发 TN-201，一种针对肌球蛋白结合蛋白 C3 相关肥厚型心肌病的基因疗法，目前处于 1 期临床试验；TN-301，一种针对保留射血分数的心力衰竭的小分子，目前处于 1 期临床试验；以及 TN-401，一种针对斑点蛋白 2 相关的心律失常性右心室心肌病的基因疗法，目前处于临床前阶段。</p>
<h2>特色文章</h2>
<ul>
<li>我们更看好的五只股票比 Tenaya Therapeutics 更好</li>
<li>什么是认沽期权成交量？</li>
<li>尽管人工智能需求激增，博通在财报后下滑</li>
<li>技术股解析：关于科技你需要知道的</li>
<li>高通刚被称为人工智能失败者——那它为什么还在上涨？</li>
<li>特殊目的收购公司（SPAC）你需要知道的</li>
<li>2 家小型生物科技公司可能会回报耐心的投资者</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5ZQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5ZQQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Tenaya Therapeutics 吗？</h2>
<p>在你考虑 Tenaya Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Tenaya Therapeutics 并不在名单上。</p>
<p>虽然 Tenaya Therapeutics 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得买入。</p>
<p>在这里查看这五只股票</p>

TNYA

<p>HC Wainwright 将 Tenaya Therapeutics 的目标股价从 5.00 美元下调至 3.00 美元，维持 “买入” 评级。该股票从当前价格来看，潜在上涨幅度为 260.14%。其他分析师的评级不一，普遍共识为 “适度买入”，目标股价为 5.50 美元。该股票交易价格为 0.83 美元，机构持股比例显著。Tenaya 专注于心脏病治疗，拥有多个在临床试验中的产品</p>

<p>Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) had its target price dropped by investment analysts at HC Wainwright from $5.00 to $3.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has a &#34;buy&#34; rating on the stock. HC Wainwright's target price would indicate a potential upside of 260.14% from the stock's current price.</p>
<div class="lb-trans"><p>Tenaya Therapeutics（纳斯达克代码：TNYA - 获取免费报告）在周五向投资者发布的报告中，投资分析师 HC Wainwright 将其目标价格从 5.00 美元下调至 3.00 美元，Benzinga 报道。该公司目前对该股票的评级为 “买入”。HC Wainwright 的目标价格意味着该股票当前价格的潜在上涨幅度为 260.14%。</p>
</div><p>TNYA has been the topic of several other research reports. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Tenaya Therapeutics in a report on Wednesday, October 8th. Chardan Capital cut their price objective on shares of Tenaya Therapeutics from $9.00 to $8.00 and set a &#34;buy&#34; rating on the stock in a research note on Friday. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $5.50.</p>
<div class="lb-trans"><p>TNYA 已经成为其他几份研究报告的主题。Weiss Ratings 在 10 月 8 日的报告中重申了对 Tenaya Therapeutics 股票的 “卖出（d-）” 评级。Chardan Capital 在周五的研究报告中将 Tenaya Therapeutics 的目标价格从 9.00 美元下调至 8.00 美元，并对该股票给予 “买入” 评级。四位分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，共识目标价格为 5.50 美元。</p>
</div><p>Get <strong>Tenaya Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Tenaya Therapeutics</strong> 的提醒：</p>
</div><p><strong>View Our Latest Stock Analysis on Tenaya Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Tenaya Therapeutics 的最新股票分析</strong></p>
</div><h2>Tenaya Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Tenaya Therapeutics 价格表现</h2>
</div><p>TNYA traded down $0.53 on Friday, reaching $0.83. 42,596,872 shares of the stock were exchanged, compared to its average volume of 3,261,775. The company's 50-day moving average price is $1.51 and its 200 day moving average price is $1.11. The firm has a market capitalization of $138.70 million, a PE ratio of -1.06 and a beta of 3.13. Tenaya Therapeutics has a fifty-two week low of $0.36 and a fifty-two week high of $2.95.</p>
<div class="lb-trans"><p>周五，TNYA 下跌 0.53 美元，达到 0.83 美元。该股票交易了 42,596,872 股，较其平均交易量 3,261,775 股有所增加。该公司的 50 日移动平均价格为 1.51 美元，200 日移动平均价格为 1.11 美元。该公司的市值为 1.387 亿美金，市盈率为-1.06，贝塔值为 3.13。Tenaya Therapeutics 的 52 周低点为 0.36 美元，52 周高点为 2.95 美元。</p>
</div><p>Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.12) earnings per share for the quarter, beating analysts' consensus estimates of ($0.15) by $0.03. As a group, equities analysts forecast that Tenaya Therapeutics will post -1.35 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Tenaya Therapeutics（纳斯达克代码：TNYA - 获取免费报告）最后一次公布季度财报是在 11 月 10 日，报告显示该公司每股收益为-0.12 美元，超出分析师共识预期的-0.15 美元，超出幅度为 0.03 美元。整体来看，股票分析师预测 Tenaya Therapeutics 在当前财政年度的每股收益为-1.35 美元。</p>
</div><h2>Hedge Funds Weigh In On Tenaya Therapeutics</h2>
<div class="lb-trans"><h2>对 Tenaya Therapeutics 的对冲基金看法</h2>
</div><p>Several large investors have recently made changes to their positions in the company. Woodline Partners LP raised its position in shares of Tenaya Therapeutics by 30,563.2% in the first quarter. Woodline Partners LP now owns 5,916,167 shares of the company's stock worth $3,373,000 after acquiring an additional 5,896,873 shares during the period. Millennium Management LLC increased its stake in shares of Tenaya Therapeutics by 561.7% in the 3rd quarter. Millennium Management LLC now owns 4,504,592 shares of the company's stock valued at $7,297,000 after purchasing an additional 3,823,848 shares in the last quarter. AQR Capital Management LLC acquired a new position in Tenaya Therapeutics in the 1st quarter worth about $442,000. Schonfeld Strategic Advisors LLC purchased a new position in shares of Tenaya Therapeutics during the 3rd quarter valued at approximately $755,000. Finally, GSA Capital Partners LLP purchased a new position in Tenaya Therapeutics during the third quarter valued at $748,000. 90.54% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>几家大型投资者最近对该公司的持仓进行了调整。Woodline Partners LP 在第一季度将其在 Tenaya Therapeutics 的持仓提高了 30,563.2%。Woodline Partners LP 目前拥有 5,916,167 股该公司的股票，价值 3,373,000 美元，在此期间又增持了 5,896,873 股。Millennium Management LLC 在第三季度将其在 Tenaya Therapeutics 的持仓增加了 561.7%。Millennium Management LLC 目前拥有 4,504,592 股该公司的股票，价值 7,297,000 美元，在上个季度又购买了 3,823,848 股。AQR Capital Management LLC 在第一季度获得了 Tenaya Therapeutics 的新头寸，价值约 442,000 美元。Schonfeld Strategic Advisors LLC 在第三季度购买了 Tenaya Therapeutics 的新头寸，价值约 755,000 美元。最后，GSA Capital Partners LLP 在第三季度购买了 Tenaya Therapeutics 的新头寸，价值 748,000 美元。目前 90.54% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About Tenaya Therapeutics</h2>
<div class="lb-trans"><h2>关于 Tenaya Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.</p>
<div class="lb-trans"><p>Tenaya Therapeutics, Inc 是一家生物技术公司，专注于在美国发现、开发和提供心脏病治疗方案。它通过基因编辑、细胞再生和基因添加来开发其产品。该公司正在开发 TN-201，一种针对肌球蛋白结合蛋白 C3 相关肥厚型心肌病的基因疗法，目前处于 1 期临床试验；TN-301，一种针对保留射血分数的心力衰竭的小分子，目前处于 1 期临床试验；以及 TN-401，一种针对斑点蛋白 2 相关的心律失常性右心室心肌病的基因疗法，目前处于临床前阶段。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Tenaya Therapeutics</li>
<li>What is Put Option Volume?</li>
<li>Broadcom Slips Post-Earnings Even as AI Demand Goes Parabolic</li>
<li>Technology Stocks Explained: Here's What to Know About Tech</li>
<li>Qualcomm Just Got Called an AI Loser—So Why Is It Rallying?</li>
<li>Special Purpose Acquisition Company (SPAC) What You Need to Know</li>
<li>2 Small-Cap Biotechs That Could Reward Patient Investors</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Tenaya Therapeutics 更好</li>
<li>什么是认沽期权成交量？</li>
<li>尽管人工智能需求激增，博通在财报后下滑</li>
<li>技术股解析：关于科技你需要知道的</li>
<li>高通刚被称为人工智能失败者——那它为什么还在上涨？</li>
<li>特殊目的收购公司（SPAC）你需要知道的</li>
<li>2 家小型生物科技公司可能会回报耐心的投资者</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5ZQQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=TNYA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Tenaya Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Tenaya Therapeutics 吗？</h2>
</div><p>Before you consider Tenaya Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Tenaya Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tenaya Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Tenaya Therapeutics 并不在名单上。</p>
</div><p>While Tenaya Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Tenaya Therapeutics 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得买入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Tenaya Therapeutics（NASDAQ:TNYA）在 HC Wainwright 被设定了新的 3.00 美元目标价